Skip to main content
SpringerLink
Log in

Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Age is a major risk factor for solid tumors, including breast cancer. The majority of elderly breast cancer patients have oestrogen-dependent tumors, thus, tamoxifen is widely administered. However, it has been noted that tamoxifen-related thrombotic events are not exceptional. Due to the increasing prevalence of comorbidity, including vascular diseases, with age, such events are more frequently observed in the aged patients. Formestane, a selective steroidal aromatase inhibitor, may represent a therapeutic option after failure with tamoxifen, or in the presence of vascular diseases contraindicating its administration. The present report provides a new clinical experience on a consecutive series of 45 elderly breast cancer women affected by moderate to severe degree of comorbidity and disability measured by a Comprehensive Geriatric Assessment (CGA) scale validated on oncological patients. Formestane was given intramuscularly at the dose of 250 mg every 2 weeks. The study included 31 patients who had metastatic disease, and 14 who received formestane as an adjuvant treatment. Median age was 74 years (range 65–93), with nine patients > 80 years. Median ECOG Performance Status (PS) was one. The more frequent comorbidities observed in our series were arthrosis-arthritis (64.4% of patients), hypertension (44.4%), vascular diseases (35.5%), CNS diseases (28.8%). Twenty percent of patients presented at least one dependency in Activities of Daily Living (ADL) and 51.2% in Instrumental Activities of Daily Living (IADL). The treatment was well tolerated – only two patients interrupted formestane because of minor adverse reaction at the injection site and generalised itching. In particular Formestane was not responsible for any worsening of pre-treatment comorbidities, especially hypertension and vascular diseases. Objective responses (OR) were observed in 11.1% of advanced patients, while the disease was stabilised in 51.8% subjects. Median duration of OR was 12 months; median overall survival was 11 months. Among patients receiving formestane as adjuvant treatment, three relapsed, with a time to failure (TTF) of 12 months. Formestane is effective and minimally toxic in an elderly breast cancer population with comorbidities and disabilities measured by CGA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vercelli M, Quaglia A, Casella C, Parodi S, Capocaccia R, Martinez Garcia C: Relative survival in elderly cancer patients in Europe. EUROCARE Working Group. Eur J Cancer 34 (14 Spec No): 2264–2270, 1998

    Google Scholar 

  2. Pratap R, Shousha S: Breast carcinoma in women under the age of 50: relationship between p53 immunostaining, tumour grade, and axillary lymph node status. Breast Cancer Res Treat 49(1): 35–39, 1998

    Google Scholar 

  3. Newman LA, Alfonso AE: Age-related differences in breast cancer stage at diagnosis between black and white patients in an urban community hospital. Ann Surg Oncol 4(8): 655-662, 1997

    Google Scholar 

  4. Fisher CJ, Egan MK, Smith P, Wicks K, Millis RR, Fentiman I: Histopathology of breast cancer in relation to age. Br J Cancer 75(4): 593–596, 1997

    Google Scholar 

  5. Goldhirsch A, Glick JH, Gelber RD, Senn H-J: Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90(21): 1601–1608, 1998

    Google Scholar 

  6. Taylor SG 4th, Gelman RS, Falkson G, Cummings FJ: Combination chemoterapy compared to Tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med 104: 455–461, 1986

    Google Scholar 

  7. Harris JR, Lippman ME, Veronesi U, Willet W: Breast cancer, part 3. New Engl J Med 327: 473–480, 1992

    Google Scholar 

  8. Johnston SRD, Dowsett M, Smith IE: Towards a molecular basis for tamoxifen resistance in breast cancer. Ann Oncol 3: 503–511, 1992

    Google Scholar 

  9. Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U: Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Int Med 156(16): 1806–1810, 1996

    Google Scholar 

  10. Powles TJ, Jones AL, Ashley SE, O'Brien ME, Tidy VA, Treleavan J, Cosgrove D, Nash AG, Sacks N, Baum M: The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31(1): 73–82, 1994

    Google Scholar 

  11. Bertelli G, Pronzato P, Amoroso D, Cusimano MP, Conte PF, Montagna G, Bertolini S, Rosso R: Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and thrombin III levels. Breast Cancer Res Treat 12: 307–310, 1988

    Google Scholar 

  12. Jankowski J, Ramlau C, Kopczynski Z, Boryska M: The influence of tamoxifen on plasma coagulation and serous fibrinolysis. Eur J Gynaecol Oncol 14 Suppl: 155–158, 1993

    Google Scholar 

  13. Chang J, Powles TJ, Ashley SE, Gregory RK, Tidy VA, Treleaven JG, Singh R: The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study. Ann Oncol 7(7): 671–675, 1996

    Google Scholar 

  14. Bagdade JD, Wolter J, Subbaiah PV, Ryan W: Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocr Metab 70(4): 1132–1135, 1990

    Google Scholar 

  15. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with nodenegative breast cancer. J Natl Cancer Inst 82(16): 1327–1332, 1990

    Google Scholar 

  16. Dziewulska-Bokiniec A, Wojtacki J, Skokowski J, Wroblewska M: Lipoprotein profile in breast cancer women: effect of tamoxifen treatment. Neoplasma 41(6): 337–340, 1994

    Google Scholar 

  17. Ilanchezhian S, Thangaraju M, Sachdanandam P: Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status. Cancer Biochem Biophy 15(2): 83–90, 1995

    Google Scholar 

  18. Vrbanec D, Reiner Z, Belev B, Plestina S: Changes in serum lipid and lipoprotein levels in postmenopausal patients with node-positive breast cancer treated with tamoxifen. Tumori 84(6): 687–690, 1998

    Google Scholar 

  19. Wasan KM, Ramaswamy M, Haley J, Dunn BP: Administration of long-term tamoxifen therapy modifies the plasma lipoprotein-lipid concentration and lipid transfer protein I activity in postmenopausal women with breast cancer. J Pharm Sci Jul 86(7): 876–879, 1997

    Google Scholar 

  20. Dowsett M: Aromatase inhibition: basic concept, and the pharmacodynamics of formestane. Ann Oncol 5(7): S3–S5, 1994

    Google Scholar 

  21. Brodie AM, Garrett WM, Hendrickson JR, Tsai-Morris CH, Williams JG: Aromatase inhibitors, their pharmacology and application. J Steroid Biochem 19: 53–58, 1983

    Google Scholar 

  22. Coombes RC, Goss P, Dowsett M, Gazet JC, Brodie AMH: 4-hydroxy-androstenedione treatment of postmenopausal patients with advanced breast cancer. Lancet 2: 1237–1239, 1984

    Google Scholar 

  23. Goss PE, Powles TJ, Dowsett M, Hutchinson G, Brodie AMH, Gazet JC, and Coombes RC: Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report. Cancer Res 46: 4823–4826, 1986

    Google Scholar 

  24. Wiseman LR, McTavish D: Formestane. Drugs 45: 66–84, 1993

    Google Scholar 

  25. Noberasco C, Bajetta E, Zilembo N, Di Leo A, Cappuzzo F, Bartoli C, Bono A, Bichisao E: Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. Oncology 52(6): 454–457, 1995

    Google Scholar 

  26. Zilembo N, Bajetta E, Noberasco C, Buzzoni R, Vicario G, Bono A, Laffranchi A, Biasi G, Dolci S, Bichisao E: Formestane: an effective first-line endocrine treatment for advanced breast cancer. J Cancer Res Clin Oncol 121(6): 378–382, 1995

    Google Scholar 

  27. Repetto L, Venturino A, Vercelli M, Gianni W, Biancardi V, Casella C, Granetto C, Parodi S, Rosso R, Marigliano V: Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer 82: 760-765, 1998

    Google Scholar 

  28. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16: 1582–1587, 1998

    Google Scholar 

  29. Fratino L, Serraino D, Zagonel V: The impact of cancer on the physical function of the elderly and their utilization of health care. Cancer 83(3): 589–590, 1998

    Google Scholar 

  30. Cohen HJ: Cancer and the functional status of the elderly. Cancer 80: 1883–1886, 1997

    Google Scholar 

  31. Monfardini S, Ferrucci L, Fratino L, Del Lungo I, Serraino D, Zagonel V: Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 77(2): 395–401, 1996

    Google Scholar 

  32. WHO Handbook for Reporting Results of Cancer Treatment. WHO Geneva, 1979

  33. Cory JFG, Lønning PE: Systemic therapy in breast cancer: efficacy and cost utility. PharmacoEconomics 5: 198–212, 1994

    Google Scholar 

  34. Repetto L, Vannozzi MO, Balleari E, Venturino A, Granetto C, Bason C, Simoni C, Prencipe S, Queirolo P, Esposito M, Ghio R, Rosso R: Mitoxantrone in elderly patients with advanced breast cancer: pharmacokinetics, marrow and peripheral hematopoietic progenitor cells. Anticancer Res 19: 879–884, 1999

    Google Scholar 

  35. Clinical trial report NGB3: A phase II study of treatment with aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal patients with advanced cancer of the breast. Horsham, UK: Chiba-Geigy Limited, 1992

  36. Coombes RC: 4-hydroxyandrostenedione in the treatment of advanced breast cancer. J Cancer Res Clin Oncol 116 (suppl): 880, 1990

    Google Scholar 

  37. Hoffken K, Jonat W, Possinger K, Kolbel M, Kunz T, Wagner H, Becher R, Callies R, Friederich P, Willmanns W et al: Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal breast cancer: a phase II study. J Clin Oncol 8: 875–880, 1990

    Google Scholar 

  38. Murray P, Pitt P: Treatment of advanced breast cancer with formestane. Ann Oncol 5(7): S11–S14, 1994

    Google Scholar 

  39. Pickles T, Perry L, Murray P, Plowman P: 4-hydroxyandrostenedione - further clinical and extended endocrine observations. Br J Cancer 62: 309–313, 1990

    Google Scholar 

  40. Perez Carrion R, Alberola Candel V, Calabresi F, Michel RT, Santos R, Delozier T, Goss P, Mauriac L, Feuilhade F, Freue M et al: Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer. Ann Oncol 5(7): S19–S24, 1994

    Google Scholar 

  41. Clinical trial report AH/BC7: Open, multicentre, comparative trial of formestane (CGP 32 349 i.m. depot) versus megestrol acetate as second-line therapy in postmenopausal patients with advanced breast cancer after first-line therapy with tamoxifen. Basel: Ciba-Geigy Limited, 1995

  42. Murray P, Pitt P: Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat 35(3): 249–253, 1995

    Google Scholar 

  43. Zilembo N, Buzzoni R, Celio L, Noberasco C, Ferrari L, Laffranchi A, Vicario G, Dolci S, Bajetta E: Formestane as treatment of advanced breast cancer in elderly women. Tumori 80(6): 433–437, 1994

    Google Scholar 

  44. Rose C: Proper sequence of endocrine therapies in advanced breast cancer. Acta Oncol 35(5): 44–49, 1996

    Google Scholar 

  45. Rose C: When tamoxifen fails in the treatment of advanced breast cancer - which endocrine therapy comes next? In: Rubens RD (ed) Advanced Breast Cancer - Reassessing Hormonal Therapy. The Parthenon Publishing Group London, New York, 1995, pp 33–41

    Google Scholar 

  46. Pemberton KD, Melissari E, Kakkar VV: The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinol 4(6): 935–942, 1993

    Google Scholar 

Download references

Authors
  1. Antonella Venturino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Danila Comandini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristina Granetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Riccardo Alberto Audisio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Federico Castiglione
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Riccardo Rosso
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lazzaro Repetto
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Venturino, A., Comandini, D., Granetto, C. et al. Formestane is feasible and effective in elderly breast cancer patients with comorbidity and disability. Breast Cancer Res Treat 62, 217–222 (2000). https://doi.org/10.1023/A:1006490524736

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006490524736

Search

Navigation